Assessment of a Radiomics-based Computer-Aided Diagnosis Tool for Pulmonary nodulES

Launched by ABRAMSON CANCER CENTER AT PENN MEDICINE · Jul 28, 2023

Keywords

ClinConnect Summary

This clinical trial is looking at a new tool that uses advanced imaging technology, called a radiomics-based computer-aided diagnosis (CAD) tool, to help doctors manage pulmonary nodules—small growths in the lung that could be cancerous. The trial will compare the usual medical care that patients receive for these nodules to care that includes this new diagnostic tool. Adults between the ages of 35 and 89 who have recently been diagnosed with specific types of pulmonary nodules, measuring between 8 and 30 millimeters, may be eligible to participate.

If you join the trial, you will be randomly assigned to one of two groups: one will receive the standard care for managing your pulmonary nodules, while the other will receive that same standard care plus the new CAD tool. This means you may have access to additional information that could help your doctor make better decisions about your health. To be eligible, you need to have a recently found nodule that meets certain criteria, and there are some exclusions related to previous cancer history or specific types of nodules. The trial is currently recruiting participants, and it offers a chance to contribute to important research that could improve lung cancer diagnosis and treatment in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Male or female, aged 35-89 years
• • 2. Scheduled to be evaluated at a UPHS PN clinic
• • 3. Newly discovered solid or part-solid indeterminate PN 8-30mm in maximal diameter on CT imaging within 60 days of index clinic visit
• • 4. Chest CT imaging meeting the technical requirements for compatibility with Optellum Virtual Nodule Clinic software
• Exclusion Criteria:
• • 1. Chest CT imaging with discrete mediastinal or hilar lymphadenopathy by CT size criteria (\>10mm in maximal short-axis diameter on axial CT images)
• • 2. PNs with popcorn calcification (consistent with benign etiology)
• • 3. Pure ground-glass subsolid PNs (may be associated with lower risk of clinically significant malignancy)
• • 4. PN previously seen on CT imaging \>60 days prior to most recent CT
• • 5. More than one indeterminate PN 8-30mm in maximal diameter
• • 6. History of lung cancer
• • 7. History of active cancer within the previous 5 years
• • 8. Presence of a thoracic implant that impedes PN visualization